Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study

Md. Ismail Hosen; Mahdi Sheikh; Maria I. Zvereva; Ghislaine Scélo; Nathalie Forey; Geoffroy Durand; Catherine Voegele; Hossein Poustchi; Masoud Khoshnia; Gholamreza Roshandel; Masoud Sotoudeh; Arash Nikmanesh; Arash Etemadi; Patrice Hodonou Avogbe; Priscilia Chopard; Tiffany M. Delhomme; Matthieu Foll; Arnaud Manel; E. Vian; Elisabete Weiderpass; Farin Kamangar; Paolo Boffetta; Paul D Pharaoh; Sanford M. Dawsey; Christian C. Abnet; Paul Brennan; James McKay; Reza Malekzadeh; Florence Le Calvez‐Kelm

doi:10.1016/j.ebiom.2020.102643

Abstract

This is the authors' abstract. We don't add key points for this paper.

French Cancer League, World Cancer Research Fund International, Cancer Research UK, Tehran University of Medical Sciences, the International Agency for Research on Cancer, and the U.S. National Cancer Institute.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hosen et al. (2020) studied this question.

synapsesocial.com/papers/69d95b595e5bcb4e3b835bb2 https://doi.org/10.1016/j.ebiom.2020.102643

View Full Paper

Ask AI

Bookmark

Share

Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study

Abstract

Discussion

Cite This Study

Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from EBioMedicine

Keep reading

More related papers

More from EBioMedicine